{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-000957","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.652743+00:00","generated_at":"2026-06-02T01:58:17.726276+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivani Medical Q1 net loss $6.0M, cash $31.0M; NPM-115 IND on track for H2 2024","bullets":["Net loss of $6.0M in Q1 2024 vs $6.3M in Q1 2023; cash $31.0M at March 31, 2024, up from $22.0M.","Completed $15M registered direct offering in March 2024, extending cash runway into H2 2025.","NPM-115 IND submission on track for H2 2024; first-in-human trial planned after regulatory clearance.","Positive preclinical data: NPM-115 showed ~20% weight loss in mice, comparable to semaglutide.","Appointed Daniel Bradbury to Board; he led Amylin's development of first once-weekly GLP-1 Bydureon."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-000957","json":"https://secwatch.observer/filing/0001753926-24-000957.json","markdown":"https://secwatch.observer/filing/0001753926-24-000957.md","text":"https://secwatch.observer/filing/0001753926-24-000957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000957/0001753926-24-000957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000957/g084237_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:58:17.726276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fcca1610524aa6c2da5025211d8f5b0555e53635","claim":"Vivani Medical, Inc. reported first quarter ended March 31, 2024 results: net income Net loss during the three months ended March 31, 2024 was $6.0 million.","evidence_excerpt":"Net loss during the three months ended March 31, 2024 was $6.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000957/0001753926-24-000957-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss during the three months ended March 31, 2024 was $6.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}